250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors in Switzerland

A list of 50 angel investors and VC funds that invest in Biotechnology startups based in Switzerland. We rank investors based on the number of investments they made in Biotechnology companies from Switzerland. We update this investor list every month.

Top 50 Biotechnology Startup Investors in Switzerland

Investor Biotechnology Switzerland investments
Zürcher Kantonal Bank 27
Foundation for Technological Innovation (FIT) 22
BioMedPartners 18
Verve Ventures 16
VI Partners 14
Eclosion SA 11
Schroder Adveq 10
EQT Life Sciences 9
M Ventures 9
Sofinnova Partners 9
redalpine 9
Kinled Holding 7
GoBeyond 7
Versant Ventures 7
HTGF | High-Tech Gruenderfonds 7
Novartis Venture Fund 6
Novo Holdings 6
Index Ventures 6
Bernina BioInvest 6
Pureos Bioventures 5
Swisscom Ventures 5
4FO Ventures 5
New Enterprise Associates 4
Aravis Ventures 4
Gilde Healthcare 4
Lichtsteiner Foundation 4
Penny Schiffer 4
Fongit Seed Invest 4
Neomed Management 4
Aargauische Kantonalbank 4
Omega Funds 4
Founderful 4
Endeavour Vision 4
Polytech Ventures 3
SICTIC 3
Inserm Transfert Initiative 3
EVA Basel 3
Wille Finance 3
b2venture 3
BlueOcean Ventures 3
BB Biotech Ventures 3
OrbiMed 3
Pfizer Venture Investments 3
Aglaia BioMedical Ventures 3
Sunstone Life Science Ventures 3
Inkef 3
Broadview Ventures 3
Initiative Capital Romandie 3
Boehringer Ingelheim Venture Fund 3
4BIO Capital 2
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Zürcher Kantonal Bank VC Fund · Zürich, Zurich, Switzerland · 19 investments in the past 12 months
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more
Investment focus
  • Health Care, Medical Device, Biotechnology
  • Seed, Series A, Funding Round
  • Switzerland, Japan, Spain
Portfolio highlights
  • DataHow — DataHow is specialized in data analytics and bioprocess modeling
  • Drone Harmony AG — Drone Harmony was founded in 2016 by a team of problem solvers with a passion for drones, software and automation. From their very early days, they have set out to tackle the mathematical and engineering challenges of enabling cost-effective deployment of drone technology in industries, where existing technologies were unable to deliver.DroneHarmony reinvents the way people fly drones commercially. Its 3D flight planning software turns anyone with a drone into an inspection professional. Sophisticated algorithms reduce complex industrial inspection tasks to automated and scalable workflows.
  • Synthara Technologies — Synthara is a Zurich-based artificial intelligence (AI) company that provides system-level solutions for businesses to enhance their products or services with smart features. The company portable and wearable gadgets such as virtual reality headsets, small wireless monitoring cameras, sensor networks, have limited smart features because computingpowerful algorithms cannot be run on them. Synthara IPs provide server-class performance with an extremely low energy requirement for neural networks (10 TOPs/Watt).
Foundation for Technological Innovation (FIT) VC Fund · Lausanne, Vaud, Switzerland · 12 investments in the past 12 months
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Debt Financing, Grant, Seed
  • Switzerland, France
Portfolio highlights
  • Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
  • Xemperia — Xemperia provides diagnostic solutions that helps to detect breast cancer and early diagnosis of relapses.
  • Ex Nunc Intelligence — Ex Nunc Intelligence provides professionals with thorough summaries of legal information, credible responses to legal issues, and automated legal document preparation features.
BioMedPartners VC Fund · Basel, Basel-Stadt, Switzerland
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • Switzerland, Germany, France
Portfolio highlights
  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Verve Ventures VC Fund · Zug, Zug, Switzerland · 22 investments in the past 12 months
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
  • Health Care, Software, Biotechnology
  • Series A, Seed, Series B
  • Switzerland, Germany, France
Portfolio highlights
  • Axelera AI — A powerful, efficient, cost-effective, and user-friendly hardware and software AI platform to accelerate computer vision in edge devices.
  • Neustark ag — Neustark enables zero-emissions concrete by capturing concrete production emissions from the atmosphere and permanently converting them to limestone. This climate positive limestone replaces cement and sand which are major cost drivers for concrete production.
  • C12 Quantum Electronics — C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.
VI Partners VC Fund · Altendorf, Schwyz, Switzerland · 3 investments in the past 12 months
VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.
Show more
Investment focus
  • Health Care, Biotechnology, Medical Device
  • Series A, Series B, Series C
  • Switzerland, Germany, United States
Portfolio highlights
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
  • Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.
Eclosion SA VC Fund · Geneva, Geneve, Switzerland
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more
Investment focus
  • Biotechnology, Pharmaceutical, Health Care
  • Seed, Series C, Funding Round
  • Switzerland
Portfolio highlights
  • KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
  • Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
  • MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Schroder Adveq VC Fund · Zürich, Zurich, Switzerland · 2 investments in the past 12 months
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • Switzerland, United States, India
Portfolio highlights
  • Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
  • Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
EQT Life Sciences VC Fund · Amsterdam, Noord-Holland, The Netherlands · 15 investments in the past 12 months
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • Binx Health — Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer
  • Onward — Working to restore movement, independence, and health in people with spinal cord injury.
  • Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 14 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
  • Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
  • Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 22 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
  • May Health — May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
redalpine VC Fund · Zürich, Zurich, Switzerland · 12 investments in the past 12 months
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Series A, Seed, Series B
  • Germany, Switzerland, United Kingdom
Portfolio highlights
  • Proxima Fusion — We are a European fusion energy startup pursuing the clearest path to grid deployment.
  • ExpressionEdits — Redefining the status quo of protein expression
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Kinled Holding VC Fund · New York, New York, United States
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more
Investment focus
  • Biotechnology, Health Care, Financial Services
  • Seed, Funding Round, Series A
  • United Kingdom, United States, Switzerland
Portfolio highlights
  • Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
  • OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
  • Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.
GoBeyond VC Fund · Zürich, Zurich, Switzerland
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more
Investment focus
  • Information Technology, Medical, Software
  • Funding Round, Seed, Series A
  • Switzerland, Germany, United Kingdom
Portfolio highlights
  • LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
  • AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
  • Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
Versant Ventures VC Fund · Menlo Park, California, United States · 8 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
  • Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
HTGF | High-Tech Gruenderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 53 investments in the past 12 months
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
  • Software, Information Technology, Biotechnology
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
  • Heidelberg Epignostix — Heidelberg Epignostix is a pioneering start-up led by a dedicated team of DNA methylation-based tumor categorization experts. Heidelberg Epignostix has revolutionized tumor categorization by using the strength of methylation-based algorithms.
  • InSpacePropulsion Technologies — ISPTech is a Spin-Off of the Institute of Space Propulsion at the German Aerospace Center (DLR). It offers non-toxic, green propulsion solutions
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 5 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 16 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • CIRCTEC — CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals. It focus is on innovation and technology leadership, scaling sustainability in the chemical, petrochemical and oil sectors.
  • CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Index Ventures VC Fund · San Francisco, California, United States · 47 investments in the past 12 months
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more
Investment focus
  • Software, E-Commerce, Internet
  • Series A, Series B, Seed
  • United States, United Kingdom, France
Portfolio highlights
  • Rohlik — Rohlik is an innovative grocery delivery startup that offers a 90-minute same-day delivery service. Since its inception, Rohlik has been growing and is on track to EUR 300 mil. revenues in 2020. Rohlík was founded in 2014 by Marek Sacha and Tomas Cupr and is headquartered in Karlín, Hlavni mesto Praha, Czech Republic.
  • Wordsmith AI — Best in class legal ai for in house legal teams. Wordsmith is used by some of the best companies in the world. Powerful products include legal ai chatbot, legal ai document generation and a whole tool kit of ai for legal documents.
  • Prodia — Easy-to-use Stable Diffusion API for AI-powered image generation at 90% lower cost than AWS. Effortless scale with no infrastructure worries.
Bernina BioInvest VC Fund · Zug, Zug, Switzerland
Bernina BioInvest is an investment Firm.
Show more
Investment focus
  • Biotechnology, Health Care, Biopharma
  • Seed, Series A, Series B
  • Switzerland
Portfolio highlights
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Pureos Bioventures VC Fund · Küsnacht, Zurich, Switzerland · 6 investments in the past 12 months
Venture capital for companies developing innovative therapeutics.
Show more
Investment focus
  • Biotechnology, Therapeutics, Health Care
  • Series A, Series C, Seed
  • Switzerland, France, The Netherlands
Portfolio highlights
  • Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
  • Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Swisscom Ventures VC Fund · Zürich, Zurich, Switzerland · 4 investments in the past 12 months
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more
Investment focus
  • Software, SaaS, Information Technology
  • Funding Round, Series B, Series A
  • Switzerland, United States, United Kingdom
Portfolio highlights
  • rready — Boost internal innovation and engage employees with ready-to-use programs, accompanied by experts in intrapreneurship.
  • Pexapark — We make PPAs for renewables simple. Master your wind and solar power purchase agreements and get the tools to manage merchant risk.
  • Spacetek Technology AG — Our process control instruments measure gases in real time, delivering a full quantitative chemical analysis up to ten times per second.
4FO Ventures VC Fund · Luxembourg, Luxembourg, Luxembourg
4FO Ventures
Show more
Investment focus
  • Artificial Intelligence, Health Care, Medical
  • Series A, Seed, Series B
  • Switzerland
Portfolio highlights
  • Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
  • Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
  • ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 42 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Anterior — Lead your plan into the future.
  • Twelve Labs — Twelve Labs helps developers make programs that can see, listen, and understand the world as we do by giving them the most powerful video search API
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Aravis Ventures VC Fund · Zürich, Zurich, Switzerland
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • Switzerland, United States, Denmark
Portfolio highlights
  • Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
  • Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
  • Bellerophon Therapeutics — Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitricoxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).
Gilde Healthcare VC Fund · Utrecht, Utrecht, The Netherlands · 5 investments in the past 12 months
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series C, Series B, Series A
  • United States, The Netherlands, Germany
Portfolio highlights
  • Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
Lichtsteiner Foundation VC Fund · Berne, Bern, Switzerland · 2 investments in the past 12 months
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more
Investment focus
  • Medical, Health Care, Biotechnology
  • Seed, Series A
  • Switzerland
Portfolio highlights
  • Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
  • Testmate Health — Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.
  • Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
Penny Schiffer Angel
Penny Schiffer - CEO & Co-founder @ Raized.ai
Show more
Investment focus
  • Health Care, Medical, Finance
  • Funding Round, Seed, Series A
  • Switzerland, Germany, United Kingdom
Portfolio highlights
  • Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
  • Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
  • Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.
Fongit Seed Invest VC Fund · Plan-les-ouates, Geneve, Switzerland
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more
Investment focus
  • Health Care, Medical, Biotechnology
  • Seed, Series A, Series B
  • Switzerland
Portfolio highlights
  • EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
  • Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
  • Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Neomed Management VC Fund · Oslo, Oslo, Norway
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series C, Funding Round
  • Switzerland, United States, Italy
Portfolio highlights
  • Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
  • Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
  • JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Aargauische Kantonalbank VC Fund · Aarau, Aargau, Switzerland
Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.
Show more
Investment focus
  • Medical Device, Dental, Biotechnology
  • Series B, Series A, Seed
  • Switzerland
Portfolio highlights
  • Peripal — Introduction to Peripal and what we do. Peripal AG manufactures and distributes the patient assist device PeriSafe to allow more patients to perform peritoneal dialysis at home.
  • InterAx Biotech Ltd — InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. Work with us now!
  • ELDICO Scientific — Shaping the future of crystallography Electron Diffraction (ED) is gaining momentum in science and industry. The application of ED for performing nano-crystallography is a disruptive innovation that will open fascinating new perspectives in particular for organic compounds required in the fields of chemical, pharmaceutical and advanced materials research. The world's first dedicated horizontal electron diffractometer
Omega Funds VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Beta Bionics — Improving lives of people living with diabetes by helping to reduce the data and decision-making overload required with diabetes.
  • Endeavor BioMedicines — Endeavor BioMedicines is a clinical-stage biotechnology company developing transformational medicines for life-threatening diseases.
  • BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Founderful VC Fund · Zürich, Zurich, Switzerland · 13 investments in the past 12 months
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more
Investment focus
  • Software, Artificial Intelligence, Information Technology
  • Pre-Seed, Seed, Series A
  • Switzerland, United Kingdom, Canada
Portfolio highlights
  • 8links — Advanced Battery Tech at Scale with 8inks: Revolutionize cell design, manufacturing, and chemistry for TWh-level solutions .
  • EthonAI — The EthonAI Manufacturing Analytics System is a powerful software suite to achieve operational excellence at scale.
  • Anthropos — Anthropos is your career platform designed for individuals and companies to manage their careers at scale, inside and outside organizations.
Endeavour Vision VC Fund · Geneva, Geneve, Switzerland · 3 investments in the past 12 months
Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.
Show more
Investment focus
  • Health Care, Medical, Biotechnology
  • Series C, Series B, Series A
  • United States, Switzerland, France
Portfolio highlights
  • Gynesonics — Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California.
  • Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
  • Virtual Incision — Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications.
Polytech Ventures VC Fund · Lausanne, Vaud, Switzerland
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more
Investment focus
  • Financial Services, FinTech, Software
  • Seed, Series A, Funding Round
  • Switzerland, United States, Spain
Portfolio highlights
  • yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
  • Relai — Relai is the easiest way to invest in Bitcoin for the long-term investor. A simple and intuitive app that allows users to buy and sell Bitcoin directly from their bank account within 1 minute, without registration, KYC verification or deposits. It was founded in 2019 and is headquartered in Zurich, Switzerland.
  • Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
SICTIC VC Fund · Zürich, Zurich, Switzerland · 5 investments in the past 12 months
How to Invest in Swiss Startups That Last The SICTIC Investor community helped to fund to more than 254 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook Services For Startups We invite all
Show more
Investment focus
  • Software, Artificial Intelligence, Information Technology
  • Seed, Pre-Seed, Funding Round
  • Switzerland, Germany, United Kingdom
Portfolio highlights
  • Billte — Headquartered in Zurich, Switzerland, Billte is a FinTech startup that specializes in digitizing the invoicing for both, businesses and consumers. For businesses Billte reduces the time and cost spent on billing. Billte makes paying invoices fast and convenient providing the user with different payment methods; bank transfer, credit card, andinstallments. Billte is an online end-to-end invoicing software that does not need installation or maintenance.
  • Algorized — Algorized develops advanced technologies for human presence detection using UWB Radar.
  • Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
Inserm Transfert Initiative VC Fund · Paris, Ile-de-France, France
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more
Investment focus
  • Biotechnology, Medical, Health Care
  • Series A, Series B, Seed
  • France, Switzerland, United States
Portfolio highlights
  • Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
  • VectivBio — We Are Ironwood
  • Aelis Farma — Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways.Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
EVA Basel VC Fund · Basel, Basel-Stadt, Switzerland
EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.
Show more
Investment focus
  • Biotechnology, Medical Device, Medical
  • Seed, Series A
  • Switzerland
Portfolio highlights
  • AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
  • POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Wille Finance VC Fund · Zürich, Zurich, Switzerland · 8 investments in the past 12 months
An international, Swiss-based family office, focusing on private equity (venture & buy-out), real estate and listed assets.
Show more
Investment focus
  • Health Care, Biotechnology, SaaS
  • Seed, Series A, Series C
  • Germany, Switzerland, France
Portfolio highlights
  • Supervizor — Supervizor allows companies to automatically check all accounting and operational data, and detect errors and fraud. No setup or dry runs required.
  • StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
  • BOX ID Systems — BOX ID Systems develops and offers an end-to-end location & process mining solution to cost effectively track millions of logistics assets digitally throughout the industrial supply chain across Europe and the World - including site-to-site, on-premises and indoor buildings digital twin of supply chain processes. The system is built on aspecialized analytics software platform, sensorik tracking devices and efficient data-, device- and user-management tools, including functions to support process automation and optimization. Industrial and automotive production customers benefit from making their logistics processes more efficient and cost optimized, with 100% transparency within their critical processes throughout the entire supply chain.
b2venture VC Fund · Saint Gallen, Sankt Gallen, Switzerland · 10 investments in the past 12 months
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Series A, Seed, Series B
  • Germany, Switzerland, United Kingdom
Portfolio highlights
  • Orus Energy — Orus Energy leverages the power of AI to unlock potential of electrical flexibility in commercial buildings.
  • Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
  • Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
BlueOcean Ventures VC Fund · Plan-les-ouates, Geneve, Switzerland
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more
Investment focus
  • Health Care, Medical, Biotechnology
  • Series A, Seed, Series B
  • Switzerland, India, France
Portfolio highlights
  • nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
  • CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
  • 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
BB Biotech Ventures VC Fund · Zürich, Zurich, Switzerland
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series C, Series A, Funding Round
  • United States, Switzerland, Italy
Portfolio highlights
  • Arvinas — Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
  • AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
  • Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
OrbiMed VC Fund · New York, New York, United States · 48 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • Disc Medicine — Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
  • Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
  • Corvus Pharmaceuticals — Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Pfizer Venture Investments VC Fund · New York, New York, United States · 7 investments in the past 12 months
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Aglaia BioMedical Ventures VC Fund · Bilthoven, Utrecht, The Netherlands
Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.
Show more
Investment focus
  • Biotechnology, Therapeutics, Pharmaceutical
  • Series A, Series B, Seed
  • The Netherlands, United States, Switzerland
Portfolio highlights
  • Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
  • InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
  • Sapreme Technologies — Enabling endosomal escape
Sunstone Life Science Ventures VC Fund · Copenhagen, Hovedstaden, Denmark · 2 investments in the past 12 months
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Funding Round, Series B, Series A
  • Denmark, Sweden, Switzerland
Portfolio highlights
  • Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
  • TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Inkef VC Fund · Amsterdam, Noord-Holland, The Netherlands · 3 investments in the past 12 months
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • The Netherlands, United States, Germany
Portfolio highlights
  • Silverflow — Silverflow offers global payment technology to power financial institutions.
  • Onward — Working to restore movement, independence, and health in people with spinal cord injury.
  • Provable Markets — Our cloud-native ATS, Aurora, offers the only regulated access point to the DTCC SFT Clearing Service
Broadview Ventures VC Fund · Boston, Massachusetts, United States
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more
Investment focus
  • Health Care, Biotechnology, Medical Device
  • Series A, Seed, Debt Financing
  • United States, Canada, Israel
Portfolio highlights
  • IsomAb — IsomAb evaluate and develop isoform specific antibodies to treat disease.
  • Nyra Medical — MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar.
  • Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
Initiative Capital Romandie VC Fund
Initiative Capital Romandie is a private equity fund that focuses on technology companies based in Western Switzerland.
Show more
Investment focus
  • Health Care, Biotechnology, Medical Device
  • Series A, Series B, Series E
  • Switzerland
Portfolio highlights
  • PicoDRILL — PicoDRILL generates technology leadership for its partner/customers through cutting-edge technology for drilling needs in the nanotechnology field. picoDrill is a private company located in Lausanne, Switzerland.
  • Diagnoplex — Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity.
  • Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 3 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
  • Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
  • Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.
4BIO Capital VC Fund · London, England, United Kingdom · 3 investments in the past 12 months
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Seed, Post-IPO Equity
  • United States, France, Switzerland
Portfolio highlights
  • Entact Bio — Creating new medicines by enhancing protein function. We are scientists, entrepreneurs, drug creators, and problem solvers, working together to bring new medicines to patients who currently have few options.
  • Ascend Gene & Cell Therapies — Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
  • Araris Biotech — Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
Investors by industry
Investors by country
Investors in Switzerland by industry